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Abstract
Background: The effectiveness of pharmacological strategies exclusively targeting secondary brain damage (SBD)
following ischemic stroke, aneurysmal subarachnoid hemorrhage, aSAH, intracerebral hemorrhage (ICH), traumatic
brain injury (TBI) and bacterial meningitis is unclear. This meta-analysis studied the effect of SBD targeted treatment
on clinical outcome across the pathological entities.
Methods: Randomized, controlled, double-blinded trials on aforementioned entities with ‘death’ as endpoint were
identified. Effect sizes were analyzed and expressed as pooled risk ratio (RR) estimates with 95% confidence intervals
(CI). 123 studies fulfilled the criteria, with data on 66,561 patients.
Results: In the pooled analysis, there was a minor reduction of mortality for aSAH [RR 0.93 (95% CI:0.85–1.02)],
ICH [RR 0.92 (95% CI:0.82–1.03)] and bacterial meningitis [RR 0.86 (95% CI:0.68–1.09)]. No reduction of mortality
was found for ischemic stroke [RR 1.05 (95% CI:1.00–1.11)] and TBI [RR 1.03 (95% CI:0.93–1.15)]. Additional analysis
of “poor outcome” as endpoint gave similar results. Subgroup analysis with respect to effector mechanisms
showed a tendency towards a reduced mortality for the effector mechanism category “oxidative metabolism/
stress” for aSAH with a risk ratio of 0.86 [95% CI: 0.73–1.00]. Regarding specific medications, a statistically
significant reduction of mortality and poor outcome was confirmed only for nimodipine for aSAH and
dexamethasone for bacterial meningitis.
Conclusions: Our results show that only a few selected SBD directed medications are likely to reduce the rate of
death and poor outcome following aSAH, and bacterial meningitis, while no convincing evidence could be found
for the usefulness of SBD directed medications in ischemic stroke, ICH and TBI. However, a subtle effect on good
or excellent outcome might remain undetected. These results should lead to a new perspective of secondary
reactions following cerebral injury. These processes should not be seen as suicide mechanisms that need to be
fought. They should be rather seen as well orchestrated clean-up mechanisms, which may today be somewhat
too active in a few very specific constellations, such as meningitis under antibiotic treatment and aSAH after
surgical or endovascular exclusion of the aneurysm.
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Background
The term ‘secondary brain damage (SBD)’ refers to
delayed detrimental functional and structural sequelae
after various types of acute cerebral injury. The under-
lying mechanisms are triggered by the primary ictus,
such as ischemic or hemorrhagic stroke (aneurysmal
subarachnoid, aSAH or intracerebral hemorrhage, ICH)
or traumatic brain injury (TBI) and intracranial infec-
tions [1–4]. Numerous mechanisms contributing to the
pathogenesis of SBD following the aforementioned acute
cerebral events have been identified over the past
decades, which subsequently led to the development and
clinical investigation of numerous experimental pharma-
cological treatments focused on different SBD mecha-
nisms. SBD mechanisms include impairment of cerebral
flood flow and cerebral autoregulation, metabolic dys-
function, edema formation, oxidative stress, disruption
of the blood brain barrier and inflammation [1–4].
While some SBD pathomechanisms are specific for
ischemic and hemorrhagic stroke, TBI and intracranial
infections, other mechanisms are a rather unspecific
reaction of the injured brain, such as edema and delayed
ischemia. At the present time it remains unclear whether
a pharmacological strategy targeting one specific patho-
mechanism could result in a beneficial effect on out-
come [5, 6]. Moreover, the relevance of targeted
treatment of SBD, in addition to established general
measures of critical care, e.g. avoidance of arterial
hypotension, increased intracranial pressure, hyperther-
mia, and hypoxemia, is uncertain [7–11]. We performed
a systematic review and meta-analysis to summarize the
currently available randomized clinical trials exclusively
targeting specific pathomechanisms of SBD with the aim
to improve clinical outcome following ischemic stroke,
ICH, SAH, TBI, and bacterial meningitis. In order to
obtain practically useful information we grouped the
available phase III randomized clinical trials according
to addressed pathomechanisms.
Methods
For this systematic review we used the Cochrane Collabor-
ation format [12] and followed the PRISMA checklist [13].
Search strategy for identification of studies
The authors conducted a systematic search of the
Pubmed database (http://www.ncbi.nlm.nih.gov/
pubmed) in February 2015 for the terms ischemic stroke,
brain infarction, subarachnoid hemorrhage, SAH, intra-
cerebral hemorrhage, intracranial hemorrhage, ICH,
traumatic brain injury, brain trauma, TBI and bacterial
meningitis. The search was limited to ‘randomized con-
trolled trials’, ‘human studies’ and ‘English’. Additionally,
previous review articles or meta-analyses were searched
for studies matching our inclusion criteria. The retrieved
articles were screened for relevance in a step-wise
manner: First the titles were reviewed, then the
corresponding abstract and in case of further uncertainty
the full-text was screened by the two first authors (TB
and HJS) until all retrieved articles were either included
or omitted.
Types of studies
Randomized, blinded, controlled clinical trials studying
the efficacy of pharmacological treatment to reduce poor
outcome or death due to SBD following ischemic stroke,
aneurysmal subarachnoid hemorrhage (aSAH), intracere-
bral hemorrhage (ICH), traumatic brain injury (TBI) and
bacterial meningitis were included, irrespective of the type
of treatment. All studies analyzing therapy of the primary
pathomechanisms, e.g. thrombolysis and recanalization
for ischemic stroke or antibiotics for meningitis were
excluded. Studies potentially targeting both the primary
pathomechanism and SBD, e.g. surgical evacuation of
intracerebral hemorrhage, were excluded to avoid bias.
SBD was defined as all adverse events occurring dur-
ing of the first three weeks following acute brain injury,
i.e. all mechanisms that are triggered by the primary
ictus, ultimately resulting in brain oedema, micro- and
macrovascular narrowing or spasm, progressive cerebral
infarction and/or hemorrhage [2, 4, 14]. On a molecular
level such mechanisms comprise metabolic disturbance,
inflammatory response, excitotoxicity, oxidative stress
and apoptosis [1, 15, 16].
Trials with different outcome parameters other than
death and/or poor neurological outcome as well as studies
where outcome data could not be extracted due to inad-
equate reporting had to be excluded. Poor neurological
outcome, i.e. severe disability and/or vegetative state or
death was measured either using the modified Rankin
Scale (mRS), the (extended) Glasgow Outcome Scale
(GOS) or the Barthel Index (BI). If a study provided num-
bers on the individual categories, data were summarized
according to the definition of poor outcome as a score of
3 to 6 on the mRS, 1 to 3 on the GOS or less than or equal
to 70% on the BI. When an inverted GOS was used, data
were readjusted to the original scale. If a study provided
the percentage of patients with an outcome event, the
actual numbers were calculated from the percentages.
Grouping of included studies
The included trials were classified according to the
addressed pathology; ischemic stroke, ICH, aSAH, TBI,
and intracranial infections as well as according to the
addressed pathomechanism or pharmacological class
respectively. Here we distinguished the categories 1) blood
pressure modification/vasodilatation, 2) hematology/im-
munology, 3) lipid metabolism, 4) neurotransmission, 5)
oxidative metabolism/stress and 6) other.
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Statistics
Data were processed using the Review Manager 5.3.0 as
supplied by the Cochrane Collaboration. Effect sizes
were expressed as pooled risk ratio (RR) estimates. Ana-
lyses for death and poor outcome were performed for
the entire type of injury cohorts as well as for subgroups
according to common pharmacological classes. Statis-
tical uncertainty was expressed in 95% confidence inter-
vals (CI). Irrespective of the probability value of the I2
test, we exclusively used random-effects models for all
pooled data analyses because of the heterogeneous sam-
ple sizes among the underlying patient populations.
Risk of bias of the included studies was assessed by
reviewing methodology for allocation concealment and
adequate blinding.
Results
Out of a total of 5299 reports, ultimately data from 123
studies targeting specific pathomechanisms of SBD fulfilled
the specified criteria and the corresponding data on a total
of 66,561 patients was included in the analysis (Fig. 1). The
corresponding references for the included studies as well as
the complete risk of bias assessment are provided in the
online supplementary information (Additional file 1).
Data on poor outcome was available in 67% of the
included studies.
Ischemic stroke meta-analysis
Out of a total of 2493 studies, ultimately 45 met our
selection criteria. The majority of studies (n = 29)
excluded patients with severe obtundation or coma.
Several studies (n = 19) excluded patients with mild or
no symptoms (i.e. NIHSS score < 4–8). Thus the
typical patient enrolled in the majority of studies
would have a moderate to severe ischemic stroke. A
total of 30,435 patients were randomized into either
experimental (15,904 patients) or control treatment
(14,531 patients). The outcome was assessed after
3 months in 75.6% of studies. The overall risk ratio
for death (Fig. 2) in the pooled analysis of all trials
was 1.05 [95% CI: 1.00–1.11] (p = 0.05). For poor
outcome (Fig. 2), data was available for 22,297
Fig. 1 PRISMA flow chart for the current meta-analysis
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patients and the overall risk ratio in the pooled ana-
lysis was 0.98 [95% CI: 0.95–1.01] (p = 0.23). Two
studies investigating the effect of erythropoietin and
diazepam reported a significant detrimental effect
with regard to death as endpoint [17, 18].
The subgroup analysis (Fig. 2) demonstrated a det-
rimental effect on death for the effector mechanism
category “hematology/immunology” with a risk ratio
of 1.27 [95% CI: 1.03–1.57] (p = 0.03).
aSAH meta-analysis
For aSAH, the initial search yielded 370 reports, of which
ultimately a total of 41 studies were included. The major-
ity of studies (n = 24) enrolled all SAH patients irrespect-
ive of severity. Eleven studies excluded comatose or
moribund patients (i.e. WFNS grade 5 or Hunt and Hess
grade 5), four studies excluded good grade patients (i.e.
WFNS grade 1). A total of 13,647 patients were random-
ized into experimental (7696 patients) or control
Fig. 2 Ischemic stroke meta-analysis: Pooled RR and 95% CI estimates for death and poor outcome are illustrated for studies on ischemic stroke.
The underlying treatment strategy is given in brackets. Studies are grouped according to common effector mechanisms and RR for subgroups
are included. A detailed reference list is provided in Additional file 1
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treatment (5951 patients). The outcome was assessed after
3 months in 57.5% of studies. The overall RR for death
(Fig. 3) in the pooled analysis of all trials was 0.93 [95%
CI:0.85–1.02] (p = 0.13). For poor outcome (Fig. 3) data
was available for 13,460 patients and the overall RR in the
pooled analysis was 0.94 [95% CI: 0.88–1.00] (p = 0.05).
There were no studies which demonstrated a significant
beneficial or detrimental effect on the outcome measure
‘death’. Two studies reported a significant reduction of
poor outcome [19, 20]. Regarding allocation concealment
as well as adequate blinding the risk of bias was low in
one and unclear in the other of these two studies. The risk
of bias regarding allocation concealment as well as ad-
equate blinding was unclear in this study.
The subgroup analysis (Fig. 3) showed a tendency
towards a beneficial effect for the effector mechanism
category “oxidative metabolism/stress” with RR 0.86
[95% CI: 0.73–1.00] (p = 0.05).
ICH meta-analysis
Out of a total of 970 reports, 9 studies targeting specific
SBD mechanisms after ICH were included. Four studies
Fig. 3 aSAH meta-analysis: Pooled RR and 95% CI estimates for death and poor outcome are illustrated for studies on aSAH. The underlying
treatment strategy is given in brackets. Studies are grouped according to common effector mechanisms and RR for subgroups are included. A
detailed reference list is provided in Additional file 1
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excluded comatose patients (i.e. GCS score < 5–8), three
studies required patients to be awake and two studies
enrolled all ICH patients. 2803 patients were random-
ized into either experimental (1665 patients) or control
treatment (1138 patients). The outcome was assessed
after 3 months in 88.9% of studies. The overall RR for
death (Fig. 4) in the pooled analysis of all trials was 0.92
[95% CI 0.82–1.03] (p = 0.15). For poor outcome (Fig. 4)
as an outcome measure, data was available for 2710
patients and the overall RR in the pooled analysis was
0.93 [95% CI: 0.84–1.03] (p = 0.19). One study demon-
strated a significant reduction of mortality and poor out-
come in patients receiving recombinant activated factor
VII [21]. Regarding allocation concealment as well as
adequate blinding the risk of bias was judged low in this
study. However, the expected positive effect of recom-
binant activated factor VII could not be confirmed in
the two subsequent studies.
The subgroup analysis (Fig. 4) showed no significant
effects on death for any effector mechanism.
TBI meta-analysis
A total of 20 out of 1052 studies on TBI met our inclu-
sion criteria. The majority of studies (n = 18) enrolled
patients with severe TBI, with five trials excluding
patients presenting with fixed dilated pupils. Overall,
17,058 patients were randomized into experimental
(8589 patients) or control treatment (8469 patients). The
outcome was assessed after 6 months in 70.0% of stud-
ies. Overall, the RR for death (Fig. 5) was 1.03 [95% CI
0.93–1.15] (p = 0.58). For ‘poor outcome’ (Fig. 5) data
was available for 4066 patients and the overall RR in the
pooled analysis was 1.01 [95% CI: 0.93–1.10] (p = 0.85).
One study investigating the effect of hyperbaric oxygen
treatment and one trial of high dose mannitol treatment
demonstrated a significant effect on reduction of mortal-
ity [22, 23]. Regarding the latter trial concerns have been
raised regarding adherence to principles of good
scientific practice [24]. Although the publication has not
been formally retracted, caution should be exercised
when interpreting these results. For allocation conceal-
ment the risk of bias was judged high in one, and
unclear in the other study, and with regard to adequate
blinding the risk of bias was considered high in both
these studies. Two studies, one investigating the use of
albumin for fluid resuscitation, the other methylprednis-
olone reported a significant detrimental effect on
outcome [25, 26].
The subgroup analysis (Fig. 5) showed a detrimental
effect for the effector mechanism category “immune
Fig. 4 ICH meta-analysis: Pooled RR and 95% CI estimates for death and poor outcome are illustrated for studies on ICH. The underlying
treatment strategy is given in brackets. Studies are grouped according to common effector mechanisms and RR for subgroups are included. A
detailed reference list is provided in Additional file 1
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response/inflammation”, with a RR of 1.16 [95% CI:
1.08–1.25] (p < 0.0001).
Bacterial meningitis meta-analysis
Eight out of a total of 414 studies on bacterial meningi-
tis, reporting on a total of 2618 patients, of which 1328
were randomized to experimental and 1290 to control
treatment, met our inclusion criteria. All studies investi-
gated the effect of corticosteroids in the context of
bacterial meningitis.
Overall, the RR for death (Fig. 6) in the pooled analysis
was 0.86 [95% CI 0.68–1.09] (p = 0.22). For ‘poor out-
come’ (Fig. 6) data was available for 1746 patients and
the overall risk ratio in the pooled analysis was 0.90
[95% CI: 0.76–1.07] (p = 0.22). Three studies demon-
strated a significant reduction of mortality [27–29].
For allocation concealment, risk of bias was low in 2 of
these 3 studies, and high in 1 study. For adequate blinding,
risk of bias was low in 2 studies, and high in 1 study.
Discussion
While previous meta-analyses have investigated the
effects of various experimental pharmacological or surgi-
cal treatments for specific cerebral diseases on different
outcome measures [30–34], the present meta-analysis
explores the efficacy of pharmacological treatments
solely targeting specific SBD mechanisms across the
various underlying entities. All entities analyzed in the
present study are considered to share at least partially
some common mechanisms of SBD [35–37]. In contrast
to the initial ictus, e.g. aSAH, the mechanisms causing
SBD are considered amenable for therapeutic interven-
tion and have therefore been subject of considerable
scientific efforts.
Our pooled analyses for the main pathological groups
provided risk ratios of poor outcome or death for the
experimental groups in a relatively narrow range from
0.86 to 1.03. For the subgroups of addressed pathways
the risk ratios scattered somewhat wider with a range
from 0.57 to 2.0. Since in such a pooled analysis the
effect of positive concepts and result is diluted by a lar-
ger number of negative attempts, the relatively narrow
range of the pooled results is not surprising.
For ischemic stroke, TBI and ICH the pooled risk
ratios for the experimental groups were close to one,
which leads to the conclusion that addressing SBD
could not be confirmed as a relevant therapeutic tar-
get. There were only 3 outliers in these groups, trials
Fig. 5 TBI meta-analysis: Pooled RR and 95% CI estimates for death and poor outcome are illustrated for studies on TBI. The underlying treatment
strategy is given in brackets. Studies are grouped according to common effector mechanisms and RR for subgroups are included. A detailed
reference list is provided in Additional file 1
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showing a statistically significant benefit for the
experimental group: the study by Mayer et al. [22] on
the use of recombinant activated factor VII for ICH,
the study of Rockswold et al. [23] on the use of
hyperbaric oxygen for TBI and the controversial study
of Cruz et al. [24] on the use of high dose mannitol
for TBI with mydriasis. Unfortunately, the benefit of
recombinant activated factor VII for ICH could not
be confirmed in two later trials and both trials on
TBI were not devoid of the risk of bias. The study of
Cruz et al. is subject to ongoing scientific debate due
to suspicion of data manipulation or fabrication [24].
However, the use of mannitol is widely established
and represents a slightly different concept than block-
ing a metabolic pathway or suppressing an active
reaction of the organism. Patients with TBI entered
into the trial were on the verge of brain herniation
due to cerebral edema and high dose mannitol helped
the physiological measures of compensation. In this
context the recently published RESCUE-ICP trial
using decompressive craniectomy provided similar
results [38]. Nonetheless, based on all the trials it
appears doubtful that addressing SBD can be main-
tained as a generally valid treatment concept for
ischemic stroke, TBI and ICH.
For aSAH the pooled risk ratio for poor outcome in
the experimental groups was with 0.94 clearly below 1.
A study on nimodipine showed a statistically significant
benefit and the subgroup analysis showed a tendency
towards a beneficial effect for the effector mechanism
category “oxidative metabolism/stress”. Therefore it can
be assumed that the concept of SBD as a therapeutic
target has some value for the management of aSAH in
the current setting.
Why does aSAH differ from ischemic stroke, TBI
and ICH? A possible explanation could be that during
the natural course after aSAH secondary processes
are well balanced to allow for the best possible
recovery, i.e. minimizing the chance of rebleed and
ischemic damage by vasospasm. The data of the
Cooperative Study [39] showed that during the nat-
ural course after aSAH rebleeds were less frequent in
case of vasospasm, in other words that vasospasm
protected to some degree against re-rupture. Since
the introduction of early aneurysm elimination, the
protective effect of vasospasm is no longer needed
and only the negative side effects remain, i.e. delayed
cerebral ischemia. Therefore, in the case of aSAH and
eliminated source of bleeding, blocking physiological
reactions might make some sense.
Fig. 6 Bacterial meningitis meta-analysis: Pooled RR and 95% CI estimates for death and poor outcome are illustrated for studies on bacterial
meningitis. The underlying treatment strategy is given in brackets. Studies are grouped according to common effector mechanisms and RR for
subgroups are included. A detailed reference list is provided in Additional file 1
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Methylprednisolone showed a marginally significant
benefit for aSAH in one study [21], while corticosteroids
were shown to be ineffective or even toxic for TBI and
ICH. In the light of the above remarks regarding calcium
antagonists it appears that corticosteroids likely benefit
patients after aSAH, but corticosteroids have not been
appropriately evaluated for aSAH.
Dexamethasone was shown in a number of, although
marginally powered, studies to reduce the chance of
death or poor outcome in patients with bacterial
meningitis. The setting of meningitis is interesting.
Similar to aSAH, the current setting with antibiotic
treatment differ widely from the natural course and the
natural secondary reactions of the immune system are
not optimally adapted to the current situation, or in
other words, the natural defense and clean-up mecha-
nisms may become activated more than necessary
under antibiotic treatment and therefore lead to
unnecessary harm.
While the actual analysis could confirm a beneficial
effect of pharmacological treatment of SBD only for
aSAH and intracranial infection, cohort and population-
based studies have clearly demonstrated a distinct reduc-
tion of overall mortality across all stroke entities and
even TBI over the past decades [32, 38, 39]. In view of
the absent or very limited effect of SBD directed treat-
ments for ischemic stroke, ICH and TBI, it must be con-
cluded that the positive time-trends during the last
decades were mainly achieved by more aggressive early
management and improved general measures of critical
care [40]. Furthermore, treatments targeting the primary
cause of brain damage, e.g. thrombectomy for ischemic
stroke, seem to be generally more efficacious than stud-
ies focusing on sole neuroprotection or targeted reduc-
tion of specific SBD mechanisms [41–46]. It must be
assumed that the extent of primary brain injury per se is
by far the dominant prognostic factor. This causality
seems to be especially valid for aSAH and ICH but also
for ischemic stroke or TBI [44–50].
Our study has several limitations: First, a pooled ana-
lysis of treatment effects among different entities may
certainly be controversial due to heterogeneous studies
or therapeutic interventions per se. Nevertheless, the
aim of this study was to illustrate the status quo of the
overall effect of specific treatment of SBD for each entity
and to highlight some potential explanations. Second,
we primarily focused on death as a robust outcome
event, since there were heterogeneous definitions for
poor functional outcome in the majority of the under-
lying trials. However, both of these endpoints are not
specific for SBD. We accounted for this by excluding tri-
als that target both primary and secondary causes of
brain injury. We cannot state with absolute certainty
that we did not exclude by this an effective treatment
concept actually working on SBD rather than the pri-
mary cause. Moreover, variations in outcome severity
distribution might be inherent to the underlying condi-
tions: While the mortality rate in patients undergoing
endovascular thrombectomy for large-vessel stroke is
15%, the mortality for aSAH can be as high as 44% and
for TBI as high as 72%, depending on regional or age-
related factors, respectively [51–53]. Accordingly, in
conditions with a relatively small proportion of fatal and
poor outcomes, our approach might underestimate rela-
tively subtle treatment effects on good or excellent out-
comes. Third, with regard to the validity of SBD as a
useful target of treatment we cannot exclude that the
modern generally accepted critical care concepts also
used within the clinical trials contributed to the general
reduction of SBD [7–11, 54]. This may partially explain
why more specific or targeted experimental treatments
have failed to additionally improve outcome. However,
methodological problems, such as imbalances in major
baseline variables or prognostic factors, insufficient pa-
tient numbers as well as errors, noise or inconsistencies
in outcome assessment, offer an alternative explanation
why studies on SBD might fail to detect moderate treat-
ment effects that could nevertheless be clinically rele-
vant. This issue could be addressed by methodological
improvements of future randomized trials, but also by
focusing more on common data elements to facilitate
meta-analyses, or even by contributing individual patient
data for pooled analyses [55–57]. Additionally, assuming
that SBD is a useful target of treatment, negative results
of a methodologically sound trial might be related to the
compound being tested, e.g. its effectiveness for the
intended mechanism, or the pharmacokinetics and
pharmacodynamics, e.g. dosing and timing. Finally, the
strict selection criteria of included trials (only random-
ized, controlled trials) might have somewhat biased the
results due to exclusion of some larger non-randomized
observational studies.
Conclusions
In summary, our meta-analysis on targeted treatment of
specific SBD mechanisms following acute cerebral injury
showed that a few selected SBD directed medications
are likely to reduce the rate of poor outcome and death
following aSAH, bacterial meningitis and maybe TBI,
while no evidence for the usefulness of SBD directed
medications was found in ischemic stroke and ICH. The
result should lead to a new perspective of secondary re-
actions following cerebral injury. These processes should
not be seen as suicide mechanisms that need to be
fought. They should be rather seen as well orchestrated
clean-up mechanisms that may today be somewhat too
active in a few very specific constellations, such as men-
ingitis under antibiotic treatment and aSAH after
Beez et al. BMC Neurology  (2017) 17:209 Page 9 of 12
aneurysm elimination. Furthermore, these results should
stimulate increased focus on methodological and report-
ing aspects of future trials.
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in this meta-analysis are presented. (DOC 265 kb)
Abbreviations
aSAH: aneurysmal subarachnoid hemorrhage; BI: Barthel Index;
CI: Confidence Interval; GOS: Glasgow Outcome Scale; ICH: Intracerebral
hemorrhage; mRS: modified Rankin Scale (mRS); RR: Risk ratio;
SBD: Secondary brain damage; TBI: Traumatic brain injury
Acknowledgements
Not applicable.
Funding
The authors declare that they have not received any funding for the design,
data collection, analysis and interpretation of this article.
Availability of data and materials
Online supplementary information for this article is available.
Authors’ contributions
TB performed acquisition, analysis, and interpretation of data and drafted the
manuscript. NE contributed to interpretation of data and drafted the
manuscript. HJS contributed to conception and design of the study. All
authors critically revised the manuscript and gave final approval.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Neurosurgery, Medical Faculty, Heinrich-Heine-University,
Düsseldorf, Germany. 2Department of Neurosurgery, Medical Faculty,
University Hospital Mannheim, University of Heidelberg, Mannheim,
Germany.
Received: 21 March 2017 Accepted: 28 November 2017
References
1. Aronowski J, Zhao X. Molecular pathophysiology of cerebral
hemorrhage: secondary brain injury. Stroke. [Internet]. 2011 [cited 2014
Sept 26];42:1781–6. Available from: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=3123894&tool=pmcentrez&rendertype=abstract
2. Bramlett HM, Dietrich WD. Pathophysiology of cerebral ischemia and brain
trauma: similarities and differences. J Cereb Blood Flow Metab [Internet].
2004 [cited 2014 Sept 26];24:133–50. Available from: http://www.ncbi.nlm.
nih.gov/pubmed/14747740.
3. Pfister HW. Scheld WM, Brain injury in bacterial meningitis: therapeutic
implications. Curr Opin Neurol [Internet]. 1997 [cited 2014 Sept 26];10:254–9.
Available from; http://www.ncbi.nlm.nih.gov/pubmed/9229135
4. Rabinstein AA. Secondary brain injury after aneurysmal subarachnoid
haemorrhage: more than vasospasm. Lancet Neurol [Internet]. 2011 [cited
2014 Sept 26];10:593–5. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/21640652
5. Hwang BY, Appelboom G, Ayer A, Kellner CP, Kotchetkov IS, Gigante PR, et
al. Advances in neuroprotective strategies: potential therapies for
intracerebral hemorrhage. Cerebrovasc Dis. 2011;31:211–22.
6. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Inflammatory and
neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc
Dis. 2009;27(Suppl 1):48–64.
7. Becker DP, Miller JD, Ward JD, Greenberg RP, Young HF, Sakalas R. The
outcome from severe head injury with early diagnosis and intensive
management. J Neurosurg. 1977;47:491–502.
8. Elf K, Nilsson P, Enblad P. Outcome after traumatic brain injury improved by
an organized secondary insult program and standardized neurointensive
care. Crit Care Med. 2002;30:2129–34.
9. Diringer MN, Bleck TP, Hemphill JC, Menon D, Shutter L, Vespa P, et al.
Critical care management of patients following aneurysmal subarachnoid
hemorrhage: recommendations from the neurocritical care society’s
multidisciplinary consensus conference. Neurocrit Care. 2011:211–40.
10. Kramer AH, Zygun DA Neurocritical care: why does it make a difference?
Curr Opin Crit Care [Internet]. 2014;20:174–181. Available from: http://www.
ncbi.nlm.nih.gov/pubmed/24553337.
11. Torbey MT, Bösel J, Rhoney DH, Rincon F, Staykov D, Amar AP, et al.
Evidence-Based Guidelines for the Management of Large Hemispheric
Infarction. Neurocrit Care [Internet]. 2015;22:146–64. Available from: http://
link.springer.com/10.1007/s12028-014-0085-6
12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011] [Internet]. Cochrane
Collab. 2011. Available from: www.cochrane-handbook.org (accessed
Sept 2014).
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
[Internet]. 2009 [cited 2014 Sept 3];6:e1000097. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=2707599&tool=
pmcentrez&rendertype=abstract
14. Chesnut RM, Marshall LF, Klauber MR, Blunt BA, Baldwin N, Eisenberg HM, et
al. The role of secondary brain injury in determining outcome from severe
head injury. J Trauma. 1993;34:216–22.
15. Siesjö BK, Siesjö P. Mechanisms of secondary brain injury. Eur J Anaesthesiol.
1996;13:247–68.
16. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J
Anaesth. 2007:4–9.
17. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C,
Wartenberg K, et al. Recombinant human erythropoietin in the
treatment of acute ischemic stroke. Stroke [Internet]. 2009 [cited 2013
Feb 18];40:e647–56. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/19834012
18. Lodder J, van Raak L, Hilton A, Hardy E, Kessels A. Diazepam to improve
acute stroke outcome: results of the early GABA-Ergic activation study in
stroke trial. a randomized double-blind placebo-controlled trial. Cerebrovasc
Dis [Internet]. 2006 [cited 2013 Feb 18];21:120–7. Available from; http://
www.ncbi.nlm.nih.gov/pubmed/16340187
19. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, et al.
Effect of oral nimodipine on cerebral infarction and outcome after
subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ
[Internet]. 1989;298:636–42. Available from: http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid=1835889&tool=pmcentrez&rendertype=abstract
20. Ono H, Mizukami M, Kitamura K, Kikuchi H. Ticlopidine: quo vadis?
Subarachnoid hemorrhage. Agents Actions Suppl [Internet]. 1984 [cited
2014 Aug 10];15:259–72. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/6385650
21. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al.
Recombinant activated factor VII for acute intracerebral hemorrhage. N.
Engl. J. Med. [Internet]. 2005 [cited 2014 Aug 10];352:777–85. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15728810.
22. Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE. Results of a
prospective randomized trial for treatment of severely brain-injured patients
Beez et al. BMC Neurology  (2017) 17:209 Page 10 of 12
with hyperbaric oxygen. J Neurosurg [Internet], Available from. 1992;76:929–
34. http://www.ncbi.nlm.nih.gov/pubmed/1588426
23. Cruz J, Minoja G, Okuchi K, Facco E. Successful use of the new high-dose
mannitol treatment in patients with Glasgow Coma Scale scores of 3 and
bilateral abnormal pupillary widening: a randomized trial. J Neurosurg
[Internet], Available from. 2004;100, 376:–83. http://www.ncbi.nlm.nih.gov/
pubmed/15035271
24. Roberts I, Smith R, Evans S. Doubts over head injury studies. BMJ [Internet].
2007;334:392–394. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
17322250.
25. Myburgh J, Cooper DJ, Finfer S, Bellomo R, Norton R, Bishop N, et al. Saline
or albumin for fluid resuscitation in patients with traumatic brain injury. N
Engl J Med [Internet] 2007;357:874–884. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/17761591.
26. CRASH trial collaborators. Effect of intravenous corticosteroids on death
within 14 days in 10 008 adults with clinically significant head injury (MRC
CRASH trial): Randomised placebo-controlled trial. Lancet. 2004;364:1321–8.
27. de Gans J, van de Beek D. Dexamethasone in adults with bacterial
meningitis. N Engl J Med [Internet]. 2002 [cited 2014 Sept 12];347:1549–56.
Available from; http://www.ncbi.nlm.nih.gov/pubmed/12432041
28. Mathur NB, Garg A, Mishra TK. Role of dexamethasone in neonatal
meningitis: a randomized controlled trial. Indian J Pediatr [Internet]. 2013
[cited 2014 Sept 26];80:102–7. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/23054852
29. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT, et
al. Dexamethasone for the treatment of tuberculous meningitis in
adolescents and adults. N Engl J Med [Internet]. 2004 [cited 2014 Sept 26];
351:1741–51. Available from; http://www.ncbi.nlm.nih.gov/pubmed/
15496623
30. Vergouwen MDI, de Haan RJ, Vermeulen M, YBWEM R. Effect of statin
treatment on vasospasm, delayed cerebral ischemia, and functional
outcome in patients with aneurysmal subarachnoid hemorrhage: a
systematic review and meta-analysis update. Stroke [Internet]. 2010 [cited
2014 Sept 26];41:e47–52. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/19875741
31. Fritz D, Brouwer MC, van de Beek D. Dexamethasone and long-term survival
in bacterial meningitis. Neurology [Internet], Available from. 2012;79:2177–9.
http://www.ncbi.nlm.nih.gov/pubmed/23152589
32. Stein SC, Georgoff P, Meghan S, Mizra K, Sonnad SS. 150 years of treating
severe traumatic brain injury: a systematic review of progress in mortality. J
Neurotrauma [Internet]. 2010 [cited 2014 Sept 26];27:1343–53. Available
from; http://www.ncbi.nlm.nih.gov/pubmed/20392140
33. Etminan N, Vergouwen MDI, Ilodigwe D, Macdonald RL. Effect of
pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and
clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a
systematic review and meta-analysis. J Cereb Blood Flow Metab [Internet].
2011 [cited 2014 Sept 26];31:1443–51. Available from: http://www.
pubmedcentral.nih.gov/articlerender.fcgi?artid=3130329&tool=
pmcentrez&rendertype=abstract
34. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute
bacterial meningitis. Cochrane database Syst Rev [Internet]. 2013 [cited 2014
Aug 27];6:CD004405. Available from; http://www.ncbi.nlm.nih.gov/pubmed/
23733364
35. Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after
subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract
Neurol. 2007;3:256–63.
36. Macdonald RL. Delayed neurological deterioration after subarachnoid
haemorrhage. Nat Rev Neurol [Internet], Available from. 2014;10:44–58.
http://www.ncbi.nlm.nih.gov/pubmed/24323051
37. Maas AI. Neuroprotective agents in traumatic brain injury. Expert Opin
Investig Drugs. 2001;10:753–67.
38. Lovelock CE, Rinkel GJE, Rothwell PM. Time trends in outcome of
subarachnoid hemorrhage: Population-based study and systematic review.
Neurol Int. 2010 [cited 2014 Sept 26];74:1494–501. Available from: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2875923&tool=
pmcentrez&rendertype=abstract
39. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett
DA, et al. Global and regional burden of stroke during 1990-2010: findings
from the Global Burden of Disease Study 2010. Lancet [Internet]. 2014 [cited
2014 Sept 26];383:245–54. Available from; http://www.ncbi.nlm.nih.gov/
pubmed/24449944
40. Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide
stroke incidence and early case fatality reported in 56 population-based
studies: a systematic review. Lancet Neurol [Internet]. 2009 [cited 2014 Sept
26];8:355–69. Available from; http://www.ncbi.nlm.nih.gov/pubmed/
19233729
41. Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, et al.
The benefits and harms of intravenous thrombolysis with recombinant
tissue plasminogen activator within 6 h of acute ischaemic stroke (the third
international stroke trial [IST-3]): a randomised controlled trial. Lancet
[Internet]. 2012 [cited 2014 Sept 26];379:2352–63. Available from: http://
www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3386495&tool=
pmcentrez&rendertype=abstract
42. Macdonald RL, Higashida RT, Keller E, Mayer S A, Molyneux A, Raabe A, et al.
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal
subarachnoid haemorrhage undergoing surgical clipping: a randomised,
double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet
Neurol [Internet]. Elsevier Ltd; 2011 [cited 2014 Aug 10];10:618–25. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/21640651.
43. Timmons SD, Ullman JS, Eisenberg HM. Craniectomy in diffuse
traumatic brain injury. N Engl J Med [Internet]. 2011 [cited 2014 Sept
26];365:373; author reply 376. Available from; http://www.ncbi.nlm.nih.
gov/pubmed/21793755
44. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo
AJ, et al. A randomized trial of intraarterial treatment for acute ischemic
stroke. N Engl J Med. 2015;
45. Campbell BCV, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al.
Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection.
N Engl J Med [Internet]. 2015;150211090353006. Available from: http://www.
nejm.org/doi/abs/10.1056/NEJMoa1414792
46. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al.
Randomized assessment of rapid endovascular treatment of ischemic stroke
[Internet]. N Engl J Med. 2015; Available from: http://www.nejm.org/doi/full/
10.1056/NEJMoa1414905?query=featured_home
47. Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, Wijdicks EF, Muizelaar
JP, et al. Definition of delayed cerebral ischemia after aneurysmal
subarachnoid hemorrhage as an outcome event in clinical trials and
observational studies: proposal of a multidisciplinary research group. Stroke
[Internet]. 2010 [cited 2014 Sept 26];41:2391–5. Available from; http://www.
ncbi.nlm.nih.gov/pubmed/20798370
48. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen
RL. Early management of severe traumatic brain injury. Lancet [Internet].
2012 [cited 2014 Sept 26];380:1088–98. Available from; http://www.ncbi.nlm.
nih.gov/pubmed/22998718
49. Lingsma HF, Roozenbeek B, Steyerberg EW, Murray GD, AIR M. Early
prognosis in traumatic brain injury: from prophecies to predictions. Lancet
Neurol [Internet]. 2010 [cited 2014 Sept 26];9:543–54. Available from; http://
www.ncbi.nlm.nih.gov/pubmed/20398861
50. Claassen J, Bernardini GL, Kreiter K, Bates J, Du YE, Copeland D, et al. Effect
of Cisternal and Ventricular Blood on Risk of Delayed Cerebral Ischemia
After Subarachnoid Hemorrhage:: The Fisher Scale Revisited. Stroke
[Internet]. 2001 [cited 2013 Sept 28];32:2012–20. Available from: http://
stroke.ahajournals.org/cgi/doi/10.1161/hs0901.095677
51. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM,
et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a
meta-analysis of individual patient data from five randomised trials. Lancet
(London, England) [Internet]. 2016;387:1723–1731. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/26898852.
52. Nieuwkamp DJ, Setz LE, Algra A, Linn FHH, de Rooij NK, Rinkel GJE. Changes in
case fatality of aneurysmal subarachnoid haemorrhage over time, according to
age, sex, and region: a meta-analysis. Lancet Neurol [Internet]. 2009;8:635–42.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19501022.
53. Hukkelhoven CWPM, Steyerberg EW, Rampen AJJ, Farace E, Habbema JDF,
Marshall LF, et al. Patient age and outcome following severe traumatic brain
injury: an analysis of 5600 patients. J Neurosurg [Internet]. 2003;99:666–673.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/14567601.
54. Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl
R, et al. Guidelines for the management of severe traumatic brain injury. I.
Blood pressure and oxygenation. J Neurotrauma. 2007;24(Suppl 1):S7–13.
55. Clarke MJ, Stewart LA, Ox O, Clarke MJ. Systematic reviews obtaining data
from randomised controlled trials : how much do we need for reliable and
informative meta-analyses ? BMJ. 1994;309:1007–10.
Beez et al. BMC Neurology  (2017) 17:209 Page 11 of 12
56. Saver JL, Warach S, Janis S, Odenkirchen J, Becker K, Benavente O, et al.
Standardizing the structure of stroke clinical and epidemiologic research
data: the National Institute of Neurological Disorders and Stroke
(NINDS) Stroke Common Data Element (CDE) project. Stroke [Internet].
2012;43:967–973. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
22308239.
57. Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, et al. National
Institute of Neurological Disorders and Stroke common data element
project - approach and methods. Clin Trials [Internet]. 2012;9:322–329.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/22371630.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Beez et al. BMC Neurology  (2017) 17:209 Page 12 of 12
